This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 1 of 1 for:    NCT03191864 | Eosinophilic Esophagitis | United States
Previous Study | Return to List | Next Study

Efficacy, Safety, and Pharmacokinetics of APT-1011 in Subjects With Eosinophilic Esophagitis (EoE) (FLUTE)

This study is currently recruiting participants.
See Contacts and Locations
Verified September 2017 by Adare Pharmaceuticals, Inc.
Sponsor:
Information provided by (Responsible Party):
Adare Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT03191864
First received: June 15, 2017
Last updated: September 15, 2017
Last verified: September 2017
  Purpose

Eosinophilic esophagitis (EoE) is an inflammatory disease of the esophagus, characterized by eosinophilic infiltration and gastrointestinal symptoms. Swallowed, topically acting corticosteroids, such as fluticasone, appear to be effective in resolving acute clinical and pathological features of EoE.

APT-1011 is an orally disintegrating tablet (ODT) formulation of fluticasone propionate. This study is designed to compare the efficacy and safety of APT-1011 with placebo in adults with EoE for an initial 12-week treatment period, followed by an additional 40-week maintenance treatment phase. Histologic response, pharmacokinetics, and dysphagia will be assessed.


Condition Intervention Phase
Eosinophilic Esophagitis Drug: APT-1011 Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
Double Blind
Primary Purpose: Treatment
Official Title: FLUTicasone in Eosinophilic Esophagitis (FLUTE): A Randomized, Double-blind, Placebo-controlled, Dose-ranging, and Maintenance Study of APT-1011 in Subjects With Eosinophilic Esophagitis

Resource links provided by NLM:


Further study details as provided by Adare Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • Histological response [ Time Frame: Week 12 ]
    Histology (eosinophils per high power field [HPF]): percentage of subjects with ≤6 PEAK eosinophils/HPF after assessing at least 5-6 biopsies from the proximal and distal esophagus (~3 each) where the HPF area is 235 square microns (40 magnification lens with a 22 mm ocular).


Secondary Outcome Measures:
  • EoE sustained response [ Time Frame: Week 12, Week 26, and Week 52 ]
    Percentage of subjects who met the primary endpoint (histology) at Week 12 and maintained the primary endpoint at Week 26 and Week 52

  • Change from baseline EREFs at Week 12, 26, and 52 [ Time Frame: Week 12, Week 26, and Week 52 ]
    Endoscopic changes will be assessed as per the EREFs evaluation based on the following endoscopic features: edema, rings, exudates, furrows, stricture, and several miscellaneous features (crepe paper esophagus, narrow caliber esophagus, and esophageal erosions).

  • EoE histologic response [ Time Frame: Week 12, Week 26, and Week 52 ]
    Percentage of subjects with a peak eosinophils/HPF <1 and <15 at Week 12, 26 and 52.

  • Change from baseline Global EoE Symptom Score [ Time Frame: Week 52 ]
    Compared score prior to randomization to scores for 7-day recall at Week 4, 8, 12, 14, 18, 22, 26, 28, 36, 44, and 52 visits

  • Dysphagia [ Time Frame: Week 12, Week 26 and Week 52 ]
    Change in the number of dysphagia episodes at baseline (14-day period prior to randomization) compared with the 14-day period prior to the time point of interest


Other Outcome Measures:
  • HPA axis suppression [ Time Frame: baseline to Week 52 ]
    Number of subjects discontinuing due to HPA axis suppression

  • Candidiasis [ Time Frame: baseline to Week 52 ]
    Frequency of oral and esophageal candidiasis

  • Oral clearance [ Time Frame: Week 12 ]
    Oral clearance (CL/F)

  • Volume of distribution [ Time Frame: Week 12 ]
    Volume of distribution (V/F)


Estimated Enrollment: 100
Actual Study Start Date: June 30, 2017
Estimated Study Completion Date: September 30, 2018
Estimated Primary Completion Date: September 30, 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: APT-1011 1.5 mg HS
Placebo after breakfast, APT-1011 1.5 mg HS
Drug: APT-1011
APT-1011 is an orally disintegrating tablet formulation of fluticasone propionate
Other Name: Fluticasone propionate ODT
Drug: Placebo
Placebo tablets are identical in composition to APT-1011 except they exclude the active ingredient.
Other Name: Matching placebo dose
Experimental: APT-1011 1.5 mg BID
APT-1011 1.5 mg after breakfast, APT-1011 1.5 mg HS
Drug: APT-1011
APT-1011 is an orally disintegrating tablet formulation of fluticasone propionate
Other Name: Fluticasone propionate ODT
Experimental: APT-1011 3 mg HS
Placebo after breakfast, APT-1011 3 mg HS
Drug: APT-1011
APT-1011 is an orally disintegrating tablet formulation of fluticasone propionate
Other Name: Fluticasone propionate ODT
Drug: Placebo
Placebo tablets are identical in composition to APT-1011 except they exclude the active ingredient.
Other Name: Matching placebo dose
Experimental: APT-1011 3 mg BID
APT-1011 3 mg after breakfast, APT-1011 3 mg HS
Drug: APT-1011
APT-1011 is an orally disintegrating tablet formulation of fluticasone propionate
Other Name: Fluticasone propionate ODT
Placebo Comparator: Placebo BID
Placebo 30 minutes after breakfast and HS
Drug: Placebo
Placebo tablets are identical in composition to APT-1011 except they exclude the active ingredient.
Other Name: Matching placebo dose

Detailed Description:

FLUTE is a phase 2b randomized, double-blind, placebo-controlled dose-ranging clinical trial of APT-1011 versus placebo in 100 adult subjects (≥18 years of age) diagnosed with EoE. Efficacy (including histologic, endoscopic, and symptomatic response), safety, and PK of APT-1011 will be examined. Participants will be given an electronic diary to record symptoms and medication intake daily.

FLUTE will be conducted in several parts (Screening [4 weeks], followed by a 4-week Baseline Symptom Assessment, and 2 treatment parts [Part 1: 14-week Induction and Part 2: 38-week Maintenance]), with a follow-up visit to occur 2 weeks after the final dose of study drug.

In Part 1 of the study, 100 subjects will be randomized 1:1:1:1:1 to receive placebo or one of 4 active doses of APT-1011. All subjects will receive one tablet 30 minutes after breakfast and one tablet at bedtime (HS). The dosing groups include: 1.5 mg HS APT-1011, 1.5 mg twice daily (BID) (total daily dose of 3 mg) APT-1011, 3 mg HS APT-1011, and 3 mg BID (total daily dose of 6 mg) APT-1011, and placebo BID.

In Part 2, all subjects classified as histologic responders at Week 12 will continue to be treated according to the dosing group to which they were randomized, and non-responders will receive single-blind 3 mg BID. All subjects who are histologic non-responders at Week 26 will stop treatment at Week 28 and enter the 2-week follow-up and exit the study. Histologic responders at Week 26 will continue on the same dose until end-of-study at Week 52.

Subjects will complete a follow-up visit 2 weeks after the final dose of study drug. All subjects must have a final EGD within 3 weeks prior to completing the Follow-up Visit unless the subject withdraws consent or has a contraindication to EGD.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female between ≥18 and ≤75 years of age at the time of informed consent
  • Signed informed consent
  • Evidence of EoE defined by ≥15 peak eosinophils per HPF as measured from proximal and distal biopsies
  • Subject-reported history of ≥3 episodes of dysphagia in the 7 days prior to Screening
  • 7-day Global EoE Symptom Score >3 at baseline and at screening
  • Willing and able to adhere to study-related treatment regimens, procedures, and visit schedule

Exclusion Criteria:

  • Have known contraindication, hypersensitivity, or intolerance to corticosteroids;
  • Have any physical, mental, or social condition or history of illness or laboratory abnormality that in the Investigator's judgment might interfere with study procedures or the ability of the subject to adhere to and complete the study;
  • Presence of oral or esophageal mucosal infection of any type;
  • Have any mouth or dental condition that prevents normal eating;
  • Have any condition affecting the esophageal mucosa or altering esophageal motility other than EoE;
  • Use of systemic corticosteroids within 60 days prior to Screening, use of inhaled/swallowed corticosteroids within 30 days prior to Screening, or extended use of high-potency dermal topical corticosteroids within 30 days prior to Screening;
  • Initiation of an elimination diet or elemental diet within 30 days before Screening (diet must remain stable after signing ICF);
  • Morning serum cortisol level ≤5 μg/dL (138 nmol/L);
  • Use of biologic immunomodulators in the 24 weeks prior to Screening;
  • Use of calcineurin inhibitors or purine analogues, or potent cytochrome P450 (CYP) 3A4 inhibitors in the 12 weeks prior to Screening;
  • Have a contraindication to or factors that substantially increase the risk of EGD or esophageal biopsy or have narrowing of the esophagus that precludes EGD with a standard 9 mm endoscope;
  • Have a history of an esophageal stricture requiring dilatation within the previous 12 weeks prior to Screening;
  • Have initiated, discontinued or changed dosage regimen of PPIs, H2 antagonists, antacids or antihistamines for any condition such as GERD or allergic rhinitis within 4 weeks prior to qualifying endoscopy. These drugs must remain constant throughout the study.
  • A serum cortisol level <18 μg/dL (497 nmol/L) at 60 minutes with adrenocorticotropic hormone (ACTH) stimulation test using 250 μg cosyntropin (i.e., a positive result on the ACTH stimulation test).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT03191864

Contacts
Contact: Brian A Meltzer, MD (609) 450-1312 ext 4033 Brian.Meltzer@adarepharma.com
Contact: Karen Brooks, PhD (609) 450-1312 ext 4026 karen.brooks@adarepharma.com

  Show 50 Study Locations
Sponsors and Collaborators
Adare Pharmaceuticals, Inc.
Investigators
Study Director: Brian A Meltzer, MD Adare Pharmaceuticals, Inc.
  More Information

Responsible Party: Adare Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT03191864     History of Changes
Other Study ID Numbers: SP-1011-002
2016-004749-10 ( EudraCT Number )
Study First Received: June 15, 2017
Last Updated: September 15, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Adare Pharmaceuticals, Inc.:
Esophagitis
Eosinophilic Esophagitis
Fluticasone
Dysphagia
Safety
Efficacy
Pharmacokinetics
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Glucocorticoids
Orally Disintegrating Tablet

Additional relevant MeSH terms:
Esophagitis
Eosinophilic Esophagitis
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Gastroenteritis
Eosinophilia
Leukocyte Disorders
Hematologic Diseases
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Fluticasone
Anti-Inflammatory Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Dermatologic Agents
Anti-Allergic Agents

ClinicalTrials.gov processed this record on September 19, 2017